Evidence map›Paper›PMID 40581761›Full record

ArticlePain medicine (Malden, Mass.)2026

Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain.

Allison Perry, Noa Krawczyk, Hillary Samples, Silvia S Martins, Katherine Hoffman, Nicholas T Williams, Anton Hung, Rachael Ross, Lisa Doan, Kara E Rudolph and 1 more

Abstract read
In one paragraph

Article in Pain medicine (Malden, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Allison PerryDepartment of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States.ORCID 0000-0002-5745-1684
Noa KrawczykDepartment of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States.ORCID 0000-0002-7396-3938
Hillary SamplesCenter for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ 08901, United States.
Silvia S MartinsDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
Katherine HoffmanDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
Nicholas T WilliamsDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
Anton HungDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
Rachael RossDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
Lisa DoanDepartment of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States.
Kara E RudolphDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.ORCID 0000-0002-9417-7960
Magdalena CerdáDepartment of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States.

Funding

Examining the Synergistic Effects of Cannabis and Prescription Opioid Policies on Chronic Pain, Opioid Prescribing, and Opioid OverdoseR01DA045872 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CERDA, MAGDALENA, MARTINS, SILVIA SABOIA · 2019 to 2023
$4.3M
Role of disability and pain in opioid overdose: mechanism and risk mitigationR01DA053243 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kara Elizabeth Rudolph · 2022 to 2026
$3.1M
Design and analysis advances to improve generalizability of clinical trials for treating opioid use disorderR01DA056407 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kara Elizabeth Rudolph, Elizabeth A. Stuart · 2022 to 2026
$3.1M
Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatalityK01DA049950 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SAMPLES, HILLARY · 2020 to 2024
$981k
College on Problems of Drug Dependence and Board of Directors, Interdisciplinary Association of Population Health Sciences R01DA053243College on Problems of Drug Dependence and Board of Directors, Interdisciplinary Association of Population Health Sciences R01DA056407NIDA NIH HHS K01 DA049950NIDA NIH HHS K01DA049950NIDA NIH HHS R01 DA045872NIDA NIH HHS R01DA045872NIDA NIH HHS R01 DA053243NIDA NIH HHS R01DA053243NIDA NIH HHS R01 DA056407President of the Interdisciplinary Association of Population Health Sciences
6 · The paper itself

Abstract

importanceThe CDC recommends initiating opioids for pain treatment at the lowest effective dose and duration; however, how dose, duration, and drug type jointly influence opioid use disorder risk remains a critical gap not addressed by current guidelines.

objectiveWe examine how interactions between dose, duration, and other medication factors (eg, drug type) influence opioid use disorder (OUD) risk. DESIGN, SETTING, PARTICIPANTS,

interventionsUsing Medicaid claims data (2016-2019) from 25 states, we analyzed opioid-naïve adults, newly diagnosed with musculoskeletal pain who initiated opioids within 3 months of diagnosis. A 6-month washout confirmed no prior opioid exposure or musculoskeletal diagnosis. Initial opioids were categorized by "dose-days supplied" (low [>0-20 mg MME] to very high [>90 mg MME] dose, and short [1-7 days] to moderate [>7-30 days] supply) and by opioid type; physical therapy (PT) sessions were also recorded. Using Poisson regression models, we estimated the OUD risk associated with dose-days categories, adjusting for baseline demographics, clinical characteristics, and medications. We separately examined opioid dose-days and PT, and assessed PT's moderating effect on dose-days' impact.

resultsAmong 30 536 patients, half initiated opioids at 20-50 MME for 1-7 days, and 20% received PT. OUD risk was 2-3 times higher for opioids initiated for >7-30 days compared to 1-7 days across doses, and 5.5 times higher for opioids initiated for >7-30 days at >90 MME versus 1-7 days at <20 MME. PT alone, neither affected OUD risk nor mitigated the increased risk from longer or higher dose opioids.

conclusionsOur findings support the need for careful opioid prescribing and alternative pain management strategies, as the observed associations between initial prescription characteristics and OUD were not mitigated by adjunctive PT. RELEVANCE: This study demonstrated that initial opioid prescriptions of 7-30 days, especially above 90 MME/day, increased OUD risk in opioid-naïve patients with musculoskeletal pain; physical therapy did not mitigate the risk. Different opioids posed varied risks, even at the same dose and duration. Careful prescribing and alternative pain management are essential.

Indexed as

Analgesics, OpioidMusculoskeletal PainOpioid-Related DisordersAdultDose-Response Relationship, DrugFemaleHumansMaleMedicaidMiddle AgedUnited StatesAnalgesics, OpioidMedicaidmusculoskeletal painopioid use disorder (OUD)physical therapysubstances

Identifiers

PMID40581761
PMCPMC12773739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.